Durgical
EN
Open the app

BRCA and Lynch syndrome: who to test and risk-reducing options

  • Approach to a problem

Some ovarian, breast and endometrial cancers run in families. Finding the gene lets a woman act before cancer starts, and warns her relatives.

Updated

See it in 3D: Uterine tubes · Infundibulum and fimbriae · Ovaries · Body of uterus · Mammary gland lobes

What it is

BRCA1 and BRCA2 are tumour suppressor genes that repair double-strand DNA breaks by homologous recombination. An inherited faulty copy, passed on in an autosomal dominant way by mothers or fathers, raises the risk of breast and high-grade serous ovarian, tubal and peritoneal cancer, and also of pancreatic and prostate cancer and, with BRCA2, melanoma. Lynch syndrome is an inherited fault in a DNA mismatch-repair gene (MLH1, MSH2, MSH6, PMS2, or EPCAM); it raises the risk of colorectal and endometrial cancer above all, and of ovarian, stomach, small bowel, urinary tract and other cancers. Testing combines a family history, tumour tests and germline testing with genetic counselling; carriers are offered intensive screening, risk-reducing surgery and medicines, and their relatives are offered testing.

Red flags

  • Any woman with epithelial ovarian, tubal or peritoneal cancer, whatever her family history: offer germline testing.
  • Breast cancer at a young age, triple-negative or in both breasts, male breast cancer in the family, or relatives with ovarian, pancreatic or metastatic prostate cancer.
  • An endometrial or colorectal tumour that is mismatch-repair deficient, especially at a young age.
  • Several relatives on the same side with colorectal, endometrial, ovarian, stomach or urinary tract cancers, across generations.
  • A known pathogenic variant in a relative: offer that specific test (cascade testing).

Step-by-step approach

  1. Take a three-generation family history on both sides, with cancer types and ages at diagnosis.
  2. Test the tumour when there is one: mismatch-repair proteins in every endometrial and colorectal cancer; BRCA testing in ovarian cancer.
  3. Offer genetic counselling before testing: what a result means for her, her children and her siblings, and what can be done.
  4. Test an affected relative first when possible, so the family's variant is found; then offer relatives that single test.
  5. Positive result → a plan by gene: breast imaging, timing of risk-reducing surgery, colonoscopy for Lynch, and contraception choices.
  6. Negative result when the family variant is known → population risk; negative with no known variant → still manage by family history.
  7. Variant of uncertain significance → treat as uninformative and manage by family history; it may be reclassified later.

BRCA1, BRCA2 and Lynch side by side

FeatureBRCA1BRCA2Lynch syndrome
Broken repair systemHomologous recombinationHomologous recombinationMismatch repair
Main cancers in womenBreast (often triple-negative), high-grade serous ovarian and tubalBreast (often hormone-receptor positive), ovarian, pancreas, melanomaColorectal and endometrial; also ovarian, stomach, urinary tract
Ovarian riskHighest; cancers start earlierLower than BRCA1; later onsetRaised, varies with the gene
Risk-reducing gynaecological surgeryTubes and ovaries removed, typically between 35 and 40Tubes and ovaries removed, typically between 40 and 45Hysterectomy with tubes and ovaries after childbearing, timed by gene
Treatment clue in the tumourPARP inhibitorsPARP inhibitorsImmunotherapy (checkpoint inhibitors)

Keys to the differential

  • High-grade serous 'ovarian' cancer usually starts in the fimbrial end of the tube, which is why risk-reducing surgery always removes the tubes as well as the ovaries.
  • Screening for ovarian cancer with CA-125 and ultrasound has not been shown to reduce deaths; risk-reducing salpingo-oophorectomy is the measure that works.
  • Surgery before natural menopause → abrupt oestrogen loss → hot flushes, bone loss and cardiovascular risk; carriers without breast cancer are usually offered hormone therapy until the age of natural menopause.
  • Combined hormonal contraception lowers ovarian cancer risk and is an option for carriers who have not had breast cancer.
  • Breast risk in carriers is managed with yearly MRI and mammography from a younger age than average, or risk-reducing mastectomy; Lynch carriers have frequent colonoscopy.

Next step / Initial management

  • Refer to genetics or genetic counselling any woman with a red flag above; document the family tree.
  • After a diagnosis of ovarian cancer: germline (and tumour) BRCA testing for every woman, which also guides PARP inhibitor treatment.
  • Carrier: refer to a high-risk clinic for breast screening, timing of risk-reducing surgery and, in Lynch, colonoscopy.
  • Offer cascade testing to first-degree relatives, men included: sons can carry and pass on the variant.
  • Before surgery: discuss menopause, fertility and future pregnancy plans; offer fertility preservation if she has not completed her family.

Common traps

  • No family history means no BRCA test in ovarian cancer: many carriers have no known affected relatives, so every woman with epithelial ovarian cancer is offered testing.
  • Yearly CA-125 and ultrasound protect a BRCA carrier: screening has not reduced deaths, and removing the tubes and ovaries is what lowers the risk.
  • A negative test clears the family: it is only reassuring when the family's own variant is known and absent; otherwise the family history still guides care.
  • A variant of uncertain significance is a positive result: most are later classed as benign, so no surgery is based on one.
  • Removing the ovaries is enough: the cancer usually starts in the tube, so the tubes must come out too.

Test yourself

Think of the answer, then tap the question to see it.

A 58-year-old with high-grade serous ovarian cancer has no relatives with cancer. Should she have BRCA testing?

Yes. Every woman with epithelial ovarian cancer is offered testing: many carriers have no family history, and the result guides PARP inhibitor treatment and her relatives' care.

Why does risk-reducing surgery in a BRCA carrier remove the tubes and not only the ovaries?

Most high-grade serous cancers called ovarian start in the fimbrial end of the uterine tube.

An endometrial tumour from a 44-year-old shows loss of MSH2 and MSH6 proteins. What does this suggest and what follows?

Possible Lynch syndrome: offer genetic counselling and germline testing; if confirmed, she needs colonoscopy surveillance and her relatives can be tested.

A woman's sister carries a BRCA1 variant. She tests negative for that variant. What is her ovarian risk?

About the population risk: a negative result for a known family variant is a true negative.

Add to my cards (4)

Elsewhere in DurgiPedia

Connections

← All of obstetrics and gynaecology

Educational content; it does not replace assessment by a doctor or your institution's protocols, and it contains no doses. For heavy bleeding, a severe headache or blurred vision, a seizure, fever, strong abdominal pain or fewer baby movements, go to an emergency department at once.

Sources: BRCA1 and BRCA2 Mutations (StatPearls Publishing (NCBI Bookshelf), 2023); Hereditary Nonpolyposis Colon Cancer (Lynch Syndrome) (StatPearls Publishing (NCBI Bookshelf), 2025); Lynch syndrome (MedlinePlus Genetics (U.S. National Library of Medicine), 2024); Ovarian cancer: MedlinePlus Genetics (MedlinePlus, US National Library of Medicine, 2026).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.